About Cellanome
Cellanome is a Healthcare company based in Palo Alto (United States) founded in 2020 by Mostafa Ronaghi. Developer of the omic data platform for researchers. Cellanome has raised $118.65 million across 3 funding rounds. Cellanome offers products and services including Automated Platform and Live Cell Assays. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Drug Informatics. Its competitors include Cellworks, Tessera Therapeutics and Phase Genomics; 3 of its 3 listed competitors have raised funding.
Company details
Cellanome was founded in 2020 and is headquartered in Palo Alto, United States. A multi-omics platform is provided by the company for researchers, integrating synthetic biology and informatics approaches. Operations focus on handling omic data to support scientific analysis in the biotechnology sector. Services enable data processing and integration across various omics disciplines.
- Headquarters Palo Alto, United States
- Founders Mostafa Ronaghi
- SectorsHealthcare
- Email••••••••
- Website cellanome.com
- Total Equity Funding$118.65M (USD)
in 3 rounds
- Latest Funding Round$75.93M (USD), Series B
Dec 2025
Products & Services of Cellanome
Cellanome offers a comprehensive portfolio of products and services, including Automated Platform and Live Cell Assays.
Enables detailed study of cell behaviors and interactions at scale.
Facilitates iterative assays linking cell responses to perturbations.
Funding Insights of Cellanome
Cellanome has successfully raised a total of $118.65M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $75.93 million completed in December 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $118.65M
- Total Rounds 3
- Last Round Series B — $75.93M
- First Round $2.05M
(Oct 2021)
All 3 funding rounds of Cellanome with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2025 | $75.93M | Series B | – | – | – |
| Mar 2023 | $40.66M | Series A | – | – | – |
| Oct 2021 | $2.05M | Seed | – | – | – |
People of Cellanome
3 people are tracked at Cellanome (2 in leadership, 1 in team).
| Name | Role | Group |
|---|---|---|
Mostafa Ronaghi | Co-Founder | Leadership |
Chelsea Johnson | Director Talent Acquisition | Leadership |
Emily Hawkins | Sr. Staff Recruiter | Team |
Complete people profiles for Cellanome
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Cellanome
3 dated milestones of Cellanome across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Cellanome is founded.
- Funding First funding round of $2.0M.
- Funding Latest funding round, Series B, of $75.9M.
Competitors of Cellanome
Cellanome has 3 listed competitors in our database, 3 of them funded. They include Cellworks, Tessera Therapeutics and Phase Genomics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| cellworks.life | 2005 | San Jose, United States | $16.52M | Biosimulation platform developed for therapeutic design in life sciences. | ||
| tesseratherapeutics.com | 2017 | Cambridge, United States | $610M | 149 | New genome engineering technology is provided for treating multiple diseases. | |
| phasegenomics.com | 2015 | Seattle, United States | $5.75M | 19 | Laboratory and computational services for DNA proximity analysis are provided. |
Detailed competitors of Cellanome
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Cellanome
The website of Cellanome (cellanome.com) receives about 4.1K visits a month.
- Monthly visits4.1K
▼ 50.1% vs previous month
Websites whose visitors overlap most with Cellanome. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| dcvc.com | 100% | #843,153 | View details |
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Cellanome (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cellanome
Complete news archive for Cellanome
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cellanome
Cellanome was founded in 2020 and raised its 1st funding round 1 year after it was founded.
Cellanome is headquartered in Palo Alto, United States. It is registered at Palo Alto, California, United States.
Cellanome is a funded company, having raised a total of $118.65M across 3 funding rounds to date. The company's 1st funding round was a Seed of $2.05M, raised on Oct 2021.
Cellanome was founded in 2020 and is headquartered in Palo Alto, United States. A multi-omics platform is provided by the company for researchers, integrating synthetic biology and informatics approaches. Operations focus on handling omic data to support scientific analysis in the biotechnology sector. Services enable data processing and integration across various omics disciplines.
Cellanome's top competitors include Tessera Therapeutics, Phase Genomics and Cellworks.
Cellanome offers Automated Platform and Live Cell Assays.